keyword
MENU ▼
Read by QxMD icon Read
search

classical hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/29774169/phase-2-study-of-everolimus-for-relapsed-or-refractory-classical-hodgkin-lymphoma
#1
Patrick B Johnston, Lauren C Pinter-Brown, Ghulam Warsi, Kristen White, Radhakrishnan Ramchandren
Background: The current standard of care for classical Hodgkin lymphoma (HL) is multiagent chemotherapy with or without radiation. In patients who relapse or fail to respond, additional high-dose chemotherapy with autologous hematopoietic stem cell transplantation (AHSCT) can improve progression-free survival (PFS). Novel therapies are required for patients refractory to chemotherapy and AHSCT. The mammalian target of rapamycin inhibitor everolimus has shown preliminary activity in preclinical models of HL and promising efficacy in patients with relapsed or refractory HL...
2018: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29764245/pembrolizumab-versus-the-standard-of-care-for-relapsed-and-refractory-classical-hodgkin-s-lymphoma-progressing-after-brentuximab-vedotin-an-indirect-treatment-comparison
#2
Sam Keeping, Elise Wu, Keith Chan, Ali Mojebi, Shannon Allen Ferrante, Arun Balakumaran
BACKGROUND: There is significant unmet need among patients with relapsed and refractory classical Hodgkin's lymphoma (RRcHL) who have failed multiple lines of therapy, including brentuximab vedotin (BV). Pembrolizumab, an immune checkpoint inhibitor, is one possible treatment solution for this population. RESEARCH METHODS: The objective of this study was to compare progression-free survival (PFS) with standard of care (SOC) versus pembrolizumab in previously BV treated RRcHL patients...
May 15, 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29755699/sequential-immunotherapy-in-a-patient-with-primary-refractory-hodgkin-lymphoma-and-novel-mutations
#3
Richard Greil, Lisa Pleyer, Bettina Jansko, Carmen Feierabend, Lukas Rettenbacher, Olga Stiefel, Christoph Rass, Patrick Morre, Daniel Neureiter, Sigrun Greil-Ressler
Primary resistant Hodgkin lymphoma is an aggressive disease with few treatment options and short survival. Neoplastic cells of classical Hodgkin lymphoma are heavily dependent on microenvironmental stimuli, regularly express PD-L1, and a relevant proportion of relapsed patients is sensitive to blocking of the PD1/PD-L1 axis. However, response duration is limited and further treatment options are unknown but urgently needed. We report a case of a patient without relevant response to five subsequent chemotherapy regimens who immediately and dramatically responded to an anti-PD1 mab...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29755658/combined-linkage-and-association-analysis-of-classical-hodgkin-lymphoma
#4
Alastair Lawrie, Shuo Han, Amit Sud, Fay Hosking, Timothee Cezard, David Turner, Caroline Clark, Graeme I Murray, Dominic J Culligan, Richard S Houlston, Mark A Vickers
The heritability of classical Hodgkin lymphoma (cHL) has yet to be fully deciphered. We report a family with five members diagnosed with nodular sclerosis cHL. Genetic analysis of the family provided evidence of linkage at chromosomes 2q35-37, 3p14-22 and 21q22, with logarithm of odds score >2. We excluded the possibility of common genetic variation influencing cHL risk at regions of linkage, by analysing GWAS data from 2,201 cHL cases and 12,460 controls. Whole exome sequencing of affected family members identified the shared missense mutations p...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29738613/results-of-the-ahod0431-trial-of-response-adapted-therapy-and-a-salvage-strategy-for-limited-stage-classical-hodgkin-lymphoma-a-report-from-the-children-s-oncology-group
#5
Frank G Keller, Sharon M Castellino, Lu Chen, Qinglin Pei, Stephan D Voss, Kathleen M McCarten, Stacy L Senn, Allen B Buxton, Rizvan Bush, Louis S Constine, Cindy L Schwartz
BACKGROUND: The Children's Oncology Group AHOD0431 study evaluated a response-directed treatment paradigm in which minimal initial chemotherapy and low-dose radiation was received only by patients who did not achieve a complete remission, and a chemotherapy/low-dose radiation salvage regimen was received by those who had a protocol-defined, low-risk recurrence. METHODS: Patients younger than 21 years who had stage IA or IIA nonbulky disease were eligible. The treatment strategy was evaluated by determining the proportion that received minimal chemotherapy alone, the proportion that had a first or second remission without the receipt of high-dose chemotherapy/stem cell rescue or higher dose involved-field radiation therapy (>21 grays), and overall survival...
May 8, 2018: Cancer
https://www.readbyqxmd.com/read/29721365/-interleukin-10-il10-proximal-promoter-polymorphisms-beyond-clinical-response-in-classical-hodgkin-lymphoma-exploring-the-basis-for-the-genetic-control-of-the-tumor-microenvironment
#6
Gabriela Vera-Lozada, Carolina Minnicelli, Priscilla Segges, Gustavo Stefanoff, Flavia Kristcevic, Joaquin Ezpeleta, Elizabeth Tapia, Gerald Niedobitek, Mário Henrique M Barros, Rocio Hassan
Interleukin-10 (IL10) is an immune regulatory cytokine. Single nucleotide polymorphisms (SNPs) in IL10 promoter have been associated with prognosis in adult classical Hodgkin lymphoma (cHL). We analyzed IL10 SNPs -1082 and -592 in respect of therapy response, gene expression and tumor microenvironment (TME) composition in 98 pediatric patients with cHL. As confirmatory results, we found that -1082AA/AG; -592CC genotypes and ATA haplotype were associated with unfavourable prognosis: Progression-free survival (PFS) was shorter in -1082AA+AG (72...
2018: Oncoimmunology
https://www.readbyqxmd.com/read/29720488/recommendations-for-managing-pd-1-blockade-in-the-context-of-allogeneic-hct-in-hodgkin-lymphoma-taming-a-necessary-evil
#7
Charles Herbaux, Reid Merryman, Steven Devine, Philippe Armand, Roch Houot, Franck Morschhauser, Bradley Haverkos
PD-1 blockade is an effective therapy in relapsed/refractory (R/R) classical Hodgkin Lymphoma (cHL) who have relapsed after or are ineligible for autologous hematopoietic cell transplantation (HCT). While single-agent anti-PD-1 monoclonal antibodies (mAbs) are associated with high response rates and durable remissions, available results to date suggest that a large majority of patients will eventually progress on therapy. Many of these patients are potential candidates for allogeneic HCT (allo-HCT) after receiving anti-PD-1 mAbs, and allo-HCT remains for now the only treatment with demonstrated curative potential in this setting...
May 2, 2018: Blood
https://www.readbyqxmd.com/read/29716887/are-ebv-related-and-ebv-unrelated-hodgkin-lymphomas-different-with-regard-to-susceptibility-to-checkpoint-blockade
#8
Antonino Carbone, Annunziata Gloghini, Carmelo Carlo-Stella
Epstein-Barr virus (EBV)-related and EBV-unrelated classic Hodgkin lymphomas (cHLs) are morphologically and phenotypically indistinguishable. However, the tumor microenvironment of EBV-related cHLs contains higher numbers of macrophages and higher expression levels of PD-L1 than that of EBV-unrelated cHLs. Moreover, viral oncoprotein LMP-1 may sustain an immunosuppressive microenvironment by inducing/enhancing production of immunosuppressive cytokines and the expression of PD1. The presence of enhanced immunosuppressive features in EBV-related cHL should make EBV-related cHL patients more susceptible to checkpoint blockade...
May 1, 2018: Blood
https://www.readbyqxmd.com/read/29715111/chemotherapy-or-combined-modality-therapy-for-early-stage-hodgkin-lymphoma
#9
Jordan A Torok, Yuan Wu, Junzo Chino, Leonard R Prosnitz, Anne W Beaven, Grace J Kim, Chris R Kelsey
BACKGROUND/AIM: Optimizing treatment of early-stage Hodgkin lymphoma (HL) requires balancing cure with potential acute and late toxicities from treatment. We reviewed our institutional experience with chemotherapy alone (ChT) versus combined modality therapy (CMT). MATERIALS AND METHODS: Patients with stage I-II classical HL in a complete response (CR) by functional imaging after chemotherapy were included. Progression-free survival (PFS) and overall survival (OS) were calculated and a multivariate analysis (MVA) was performed...
May 2018: Anticancer Research
https://www.readbyqxmd.com/read/29708579/evaluation-of-the-prognostic-importance-of-c-myc-and-bcl-2-expressions-and-the-presence-of-epstein-barr-virus-in-classical-hodgkin-lymphoma
#10
Aydan Kiliçarslan, Vedia Öztürk, Aysun Şentürk Yikilmaz, Mehmet Doğan, Mesut Akyol
OBJECTIVE: Although classical Hodgkin lymphoma (cHL) has a relatively good prognosis, it also entails different treatment responses and involves patients who have different clinical courses. Our aim was to investigate c-Myc, Bcl-2 and EBV biomarkers in cHL and their relationship with the IPS score. MATERIAL AND METHOD: c-Myc and Bcl-2 immunohistochemical staining with EBER in situ hybridization (EBER-ISH) was applied to the paraffin sections of 94 cases diagnosed as cHL...
April 30, 2018: Türk Patoloji Dergisi
https://www.readbyqxmd.com/read/29695516/phase-1-study-of-the-pi3k%C3%AE-inhibitor-incb040093-%C3%A2-jak1-inhibitor-itacitinib-in-relapsed-refractory-b-cell-lymphoma
#11
Tycel J Phillips, Andres Forero-Torres, Taimur Sher, Catherine S Diefenbach, Patrick Johnston, Moshe Talpaz, Jennifer Pulini, Li Zhou, Peggy Scherle, Xuejun Chen, Paul M Barr
Because both phosphatidylinositol 3-kinase δ (PI3Kδ) and Janus kinase (JAK)-signal transducer and activator of transcription pathways contribute to tumor cell proliferation and survival in B-cell malignancies, their simultaneous inhibition may provide synergistic treatment efficacy. This phase 1 dose-escalation/expansion study assessed the safety, efficacy, pharmacokinetics, and pharmacodynamics of INCB040093, a selective PI3Kδ inhibitor, as monotherapy or combined with itacitinib (formerly INCB039110), a selective JAK1 inhibitor, in adult patients with relapsed or refractory (R/R) B-cell lymphomas...
April 25, 2018: Blood
https://www.readbyqxmd.com/read/29685424/immunotherapy-for-the-treatment-of-hodgkin-lymphoma-an-evolving-paradigm
#12
REVIEW
Steven M Bair, Anthony Mato, Jakub Svoboda
Classical Hodgkin lymphoma (cHL) is one of the most common lymphomas in the Western world. Although most patients are cured with standard first-line therapy, up to 20% of patients will have relapsed or refractory disease. Although the conventional approach to treatment has consisted of chemotherapy, radiation, and for those who relapse, autologous or allogeneic transplantation, newer approaches have become available in recent years, including immunoconjugates and checkpoint inhibitors. These approaches have shown significant efficacy in clinical trials and might be associated with fewer long-term toxicities compared with conventional therapies...
March 31, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29685160/advances-in-cd30-and-pd-1-targeted-therapies-for-classical-hodgkin-lymphoma
#13
REVIEW
Yucai Wang, Grzegorz S Nowakowski, Michael L Wang, Stephen M Ansell
CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolumab and pembrolizumab are highly efficacious in treating relapsed and/or refractory cHL. Ongoing studies are evaluating their efficacy in earlier lines of therapy and have demonstrated encouraging results. These agents are expected to further change the landscape of cHL management. Increased cure rates and reduced long-term toxicity from traditional chemotherapy and radiotherapy are likely with the emergence of these novel targeted therapies...
April 23, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29684805/detecting-a-rare-composite-small-bowel-lymphoma-by-magnetic-resonance-imaging-coincidentally-a-case-report-with-radiological-surgical-and-histopathological-features
#14
M Pezzella, B Brogna, A Romano, F Torelli, G Esposito, M Petrillo, F M Romano, N Di Martino, A Reginelli, R Grassi
INTRODUCTION: Diagnosing lymphoma continues to prove challenging in the clinical practice. Composite lymphoma (CL) is defined by the coexistence of different lymphoma subtypes in the same anatomical location. This condition has seldom been witnessed in the gastrointestinal (GI) tract. We weren't able to find previous cases in the literature about small bowel CL with follicular lymphoma (FL) and classical Hodgkin lymphoma (CHL). Surgery is the treatment of choice to obtain accurate histology, to manage and prevent acute complications...
April 16, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29673745/-acquired-c1-esterase-inhibitor-deficiency-via-bradykinin-mediated-angioedema-four-cases
#15
C Jacquin-Porretaz, F Castelain, E Daguindau, E Seilles, C Nardin, F Aubin, F Pelletier
BACKGROUND: Acquired C1-esterase inhibitor (C1-INH) deficiency angioedema (C1-INH-AAE) is a form of bradykinin-mediated angioedema. This rare disorder is due to acquired consumption of C1-INH, hyperactivation of the classic pathway of human complement, and potentially fatal recurrent angioedema symptoms. Clinical symptoms of C1-INH-AAE are very similar to those of hereditary angioedema (HAE) but usually appear after the fourth decade of life and induce abdominal pain less frequently. Laboratory tests are essential in establishing the diagnosis with low levels or abnormal structure and function of C1-INH...
April 16, 2018: Annales de Dermatologie et de Vénéréologie
https://www.readbyqxmd.com/read/29665938/-research-and-applications-progress-of-lenalidomide-in-relapsed-refractory-blood-system-diseases-review
#16
Wen-Jing Fan, Zhi-Qiao Fan, Tao Wu, Hai Bai
Lenalidomide, a novel immunomodulatory agent, is a kind of thalidomide derivatives, which shows a good efficacy and safety for hematological system diseases. This review is aimed to evaluate the efficacy and safety of lenalidomide in treatment of patients with multiple myeloma, chronic lymphocytic leukemia, acute myeloid leukemia, non-Hodgkin's lymphoma, classical Hodgkin's lymphoma and POEMS syndrome at their replased or refractory state. At the same time, this review focuses on the newest clinical research and the latest application progress of lenalidomide for relapsed or refractory hematological system diseases...
April 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29651360/phosphatase-of-regenerating-liver-3-prl-3-is-overexpressed-in-classical-hodgkin-lymphoma-and-promotes-survival-and-migration
#17
Magnus Aassved Hjort, Håkon Hov, Pegah Abdollahi, Esten Nymoen Vandsemb, Unn-Merete Fagerli, Bendik Lund, Tobias Schmidt Slørdahl, Magne Børset, Torstein Baade Rø
Background: Phosphatase of regenerating liver-3 (PRL-3) is implicated in oncogenesis of hematological and solid cancers. PRL-3 expression increases metastatic potential, invasiveness and is associated with poor prognosis. With this study, we aimed to show a possible oncogenic role of PRL-3 in classical Hodgkin lymphoma (cHL). Methods: PRL-3 expression was measured in 25 cHL patients by immunohistochemistry and gene expression was analyzed from microdissected malignant cells...
2018: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/29650799/pervasive-mutations-of-jak-stat-pathway-genes-in-classical-hodgkin-lymphoma
#18
Enrico Tiacci, Erik Ladewig, Gianluca Schiavoni, Alex Penson, Elisabetta Fortini, Valentina Pettirossi, Yuchun Wang, Ariele Rosseto, Alessandra Venanzi, Sofija Vlasevska, Roberta Pacini, Simonetta Piattoni, Alessia Tabarrini, Alessandra Pucciarini, Barbara Bigerna, Alessia Santi, Alessandro M Gianni, Simonetta Viviani, Antonello Cabras, Stefano Ascani, Barbara Crescenzi, Cristina Mecucci, Laura Pasqualucci, Raul Rabadan, Brunangelo Falini
Dissecting the pathogenesis of classical Hodgkin lymphoma (cHL), a common cancer in young adults, remains challenging due to the rarity of tumor cells in involved tissues (usually <5%). Here, we analyzed the coding genome of cHL by microdissecting tumor and normal cells from 34 patient biopsies, for a total of ~50,000 singly isolated lymphoma cells. We uncovered several recurrently mutated genes, namely STAT6 (32% of cases), GNA13 (24%), XPO1 (18%) and ITPKB (16%), and document the functional role of mutant STAT6 in sustaining tumor cell viability...
April 12, 2018: Blood
https://www.readbyqxmd.com/read/29623180/pembrolizumab-and-its-role-in-relapsed-refractory-classical-hodgkin-s-lymphoma-evidence-to-date-and-clinical-utility
#19
REVIEW
Polina Shindiapina, Lapo Alinari
Immune evasion is a critical mechanism of malignant cell survival, and relies in part on molecular signaling through the programmed cell death 1 (PD-1)/PD-1 ligand (PD-L1) axis that contributes to T cell exhaustion. Immune modulatory therapy with monoclonal antibodies against PD-1 designed to enhance antitumor immune response have shown promise in the treatment of advanced solid tumors and hematologic malignancies. Classical Hodgkin's lymphoma (cHL), a unique B cell malignancy characterized by an extensive but ineffective immune cell infiltrate surrounding a small number of tumor cells, has shown significant response to anti-PD-1 directed therapy...
April 2018: Therapeutic Advances in Hematology
https://www.readbyqxmd.com/read/29597249/the-role-of-activator-protein-1-ap-1-family-members-in-cd30-positive-lymphomas
#20
REVIEW
Ines Garces de Los Fayos Alonso, Huan-Chang Liang, Suzanne D Turner, Sabine Lagger, Olaf Merkel, Lukas Kenner
The Activator Protein-1 (AP-1) transcription factor (TF) family, composed of a variety of members including c-JUN, c-FOS and ATF, is involved in mediating many biological processes such as proliferation, differentiation and cell death. Since their discovery, the role of AP-1 TFs in cancer development has been extensively analysed. Multiple in vitro and in vivo studies have highlighted the complexity of these TFs, mainly due to their cell-type specific homo- or hetero-dimerization resulting in diverse transcriptional response profiles...
March 28, 2018: Cancers
keyword
keyword
49025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"